Susquehanna International Group
KZIA

Susquehanna International Group’s Kazia Therapeutics KZIA Stock Holding History

Susquehanna International Group’s Portfolio KZIA Stock Details KZIA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-484
Closed -$239K – 13188
2021
Q2 		$239K Sell
484
-652
-57% -$344K ﹤0.01% 11229
2021
Q1 		$704K Buy
+1,136
New +$594K ﹤0.01% 8643

Other funds holding KZIA

Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $117B AUM 29.66% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return
AAP
Arax Advisory Partners Denver, Colorado $3.54B AUM 19.14% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
AF
Allworth Financial Folsom, California $24.7B AUM 15.55% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Susquehanna International Group's KZIA Position: Q3 2024 in Review

Susquehanna International Group sold out of Kazia Therapeutics (KZIA) in Q3 2024, closing a stake of 830 shares — an estimated $16.6K sold.

Susquehanna International Group first reported a position in KZIA in Q3 2018 and held it in 8 quarters. The position peaked at $429K in Q4 2021. 17 funds tracked by Wall St. Rank hold KZIA as of Q3 2024.

  • Susquehanna International Group reported no remaining Kazia Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Susquehanna International Group sold 830 Kazia Therapeutics shares in Q3 2024, an estimated $16.6K.
  • Susquehanna International Group first reported a position in Kazia Therapeutics in Q3 2018 and held it in 8 quarters.
  • Susquehanna International Group's Kazia Therapeutics position peaked at $429K in Q4 2021.
  • 17 funds tracked by Wall St. Rank held Kazia Therapeutics as of Q3 2024.

Based on Susquehanna International Group's 13F filing for Q3 2024, filed 14 Nov 2024.